Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.

Xia JT, Wang H, Liang LJ, Peng BG, Wu ZF, Chen LZ, Xue L, Li Z, Li W.

Pancreas. 2012 May;41(4):629-35. doi: 10.1097/MPA.0b013e31823bcef2.

PMID:
22249132
2.

Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance.

Xue YZ, Sheng YY, Liu ZL, Wei ZQ, Cao HY, Wu YM, Lu YF, Yu LH, Li JP, Li ZS.

Tumour Biol. 2013 Apr;34(2):895-9. doi: 10.1007/s13277-012-0624-8. Epub 2012 Dec 18.

PMID:
23247867
3.

High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma.

Wang L, Gu F, Liu CY, Wang RJ, Li J, Xu JY.

Tumour Biol. 2013 Apr;34(2):853-8. doi: 10.1007/s13277-012-0617-7. Epub 2012 Dec 16.

PMID:
23242609
4.

USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma.

Ning Z, Wang A, Liang J, Xie Y, Liu J, Feng L, Yan Q, Wang Z.

Int J Oncol. 2014 Oct;45(4):1594-608. doi: 10.3892/ijo.2014.2531. Epub 2014 Jul 3.

PMID:
24993031
5.

MTA2 expression is a novel prognostic marker for pancreatic ductal adenocarcinoma.

Chen DW, Fan YF, Li J, Jiang XX.

Tumour Biol. 2013 Jun;34(3):1553-7. doi: 10.1007/s13277-013-0685-3. Epub 2013 Feb 12.

PMID:
23400716
6.

Expression of UbcH10 in pancreatic ductal adenocarcinoma and its correlation with prognosis.

Zhao ZK, Wu WG, Chen L, Dong P, Gu J, Mu JS, Yang JH, Liu YB.

Tumour Biol. 2013 Jun;34(3):1473-7. doi: 10.1007/s13277-013-0671-9. Epub 2013 Jan 26.

PMID:
23355337
7.

Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.

Liu C, Yang Z, Li D, Liu Z, Miao X, Yang L, Zou Q, Yuan Y.

Cancer Biomark. 2015;15(6):735-43. doi: 10.3233/CBM-150515.

PMID:
26406402
8.

Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.

Guo S, Jing W, Hu X, Zhou X, Liu L, Zhu M, Yin F, Chen R, Zhao J, Guo Y.

Int J Cancer. 2014 Mar 15;134(6):1369-78. doi: 10.1002/ijc.28471. Epub 2013 Oct 3.

9.

Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.

Okada K, Fujiwara Y, Takahashi T, Nakamura Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Mori M, Doki Y.

Ann Surg Oncol. 2013 Mar;20(3):1035-43. doi: 10.1245/s10434-012-2680-0. Epub 2012 Oct 2.

PMID:
23054116
10.

Overexpression of Tbx3 predicts poor prognosis of patients with resectable pancreatic carcinoma.

Wang HC, Meng QC, Shan ZZ, Yuan Z, Huang XY.

Asian Pac J Cancer Prev. 2015;16(4):1397-401.

11.

Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.

Li L, Li Z, Kong X, Xie D, Jia Z, Jiang W, Cui J, Du Y, Wei D, Huang S, Xie K.

Gastroenterology. 2014 Aug;147(2):485-97.e18. doi: 10.1053/j.gastro.2014.04.048. Epub 2014 May 20.

PMID:
24859161
12.

Cytoplasmic Forkhead box M1 (FoxM1) in esophageal squamous cell carcinoma significantly correlates with pathological disease stage.

Hui MK, Chan KW, Luk JM, Lee NP, Chung Y, Cheung LC, Srivastava G, Tsao SW, Tang JC, Law S.

World J Surg. 2012 Jan;36(1):90-7. doi: 10.1007/s00268-011-1302-5.

13.

CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma.

Wang L, Gu F, Ma N, Zhang L, Bian JM, Cao HY.

Tumour Biol. 2013 Aug;34(4):2309-13. doi: 10.1007/s13277-013-0775-2. Epub 2013 Apr 9.

PMID:
23568706
14.

DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma.

Xue YZ, Wu TL, Wu YM, Sheng YY, Wei ZQ, Lu YF, Yu LH, Li JP, Li ZS.

Tumour Biol. 2013 Oct;34(5):2857-61. doi: 10.1007/s13277-013-0846-4. Epub 2013 May 17.

PMID:
23681804
15.

MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.

Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, Sansom OJ, Evans TR, McKay CJ, Oien KA.

Clin Cancer Res. 2012 Jan 15;18(2):534-45. doi: 10.1158/1078-0432.CCR-11-0679. Epub 2011 Nov 23.

16.

Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.

Liang JJ, Wang H, Rashid A, Tan TH, Hwang RF, Hamilton SR, Abbruzzese JL, Evans DB, Wang H.

Clin Cancer Res. 2008 Nov 1;14(21):7043-9. doi: 10.1158/1078-0432.CCR-08-0381.

17.

Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer.

Bronsert P, Kohler I, Timme S, Kiefer S, Werner M, Schilling O, Vashist Y, Makowiec F, Brabletz T, Hopt UT, Bausch D, Kulemann B, Keck T, Wellner UF.

Surgery. 2014 Jul;156(1):97-108. doi: 10.1016/j.surg.2014.02.018. Epub 2014 Feb 28.

PMID:
24929761
18.

Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.

Piao J, Liu S, Xu Y, Wang C, Lin Z, Qin Y, Liu S.

Exp Mol Pathol. 2015 Feb;98(1):1-6. doi: 10.1016/j.yexmp.2014.11.003. Epub 2014 Nov 5.

PMID:
25445504
19.

Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis.

Ning Z, Wang A, Liang J, Liu J, Zhou T, Yan Q, Wang Z.

Int J Clin Exp Pathol. 2014 Apr 15;7(5):2462-9. eCollection 2014.

20.

Decreased circadian component Bmal1 predicts tumor progression and poor prognosis in human pancreatic ductal adenocarcinoma.

Li W, Liu L, Liu D, Jin S, Yang Y, Tang W, Gong L.

Biochem Biophys Res Commun. 2016 Mar 25;472(1):156-62. doi: 10.1016/j.bbrc.2016.02.087. Epub 2016 Feb 23.

PMID:
26915801

Supplemental Content

Support Center